Kuching

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Chronic myeloid leukaemia2 trials
• Myeloproliferative neoplasms2 trials
• Childhood cancers1 trial
• Chronic spontaneous urticaria1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Hidradenitis suppurativa1 trial
• Immune thrombocytopenia (ITP)1 trial
• Multiple sclerosis1 trial
• Myelodysplastic syndromes1 trial
• and 3 more

Phase

• Phase 311 trials
• Phase 1/22 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting11 trials
• Recruiting2 trials
• Terminated2 trials

Lead sponsor

• Novartis Pharmaceuticals15 trials

Running trials

• Active, not recruiting

  Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

  NCT07468071· Phase 1/2· Novartis Pharmaceuticals· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  NCT06799000· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

  NCT05677451· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

  NCT05653349· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

  NCT05445843· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

  NCT05456191· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

  NCT04940052· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT04747613· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

  NCT02584933· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source